Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Five Below Inc (FIVE) vs Zoetis Inc (ZTS) Price & Performance

Five Below IncTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Five Below Inc vs Zoetis Inc — how do they compare? Five Below Inc trades at $234.71 (market cap $13.01B), while Zoetis Inc trades at $75.36 (market cap $30.92B). The key difference: Zoetis Inc is far larger — about 2.4× Five Below Inc's market cap, and Zoetis Inc pays a 2.83% dividend while Five Below Inc pays none. Which is the better fit depends on your goals.

FIVEZTS
Market Cap
$13.01B$30.92B
Sector
Consumer StaplesHealth
52-Week High
$247.71$156.76
52-Week Low
$134.36$71.91
Enterprise Value
$13.90B$38.49B
Dividend Yield
2.83%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Five Below Inc

Five Below (FIVE) is trading at $244.37, up 5.73% with strong bullish momentum. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.22 exceeding expectations of $1.77. Technical indicators signal bullish sentiment, supported by positive moving averages. Revenue growth remains solid, projected to reach $5.1B in 2026, though net margins have compressed from 9.78% in 2022 to 6.54% in 2025. Analyst consensus is strongly bullish with 62% buy ratings and a $252.36 price target.

FIVE presents a compelling growth story with expanding revenue and strong institutional support. However, elevated valuation multiples (P/E 30.79) and compressed profit margins pose risks. The stock's proximity to 52-week highs suggests limited near-term upside without significant catalysts. Execution on store expansion and margin improvement will be critical for sustained outperformance.

Zoetis Inc

Zoetis (ZTS) trades at $72.66, down 5.92% amid a bearish technical signal and recent earnings pressure. The stock is near its 52-week low after Piper Sandler cut its price target to $80.00 on August 11, 2026. Despite strong profitability with a net margin of 27.69% and ROE of 64.91%, Q2 2026 revenue missed estimates, and the company reduced its 2026 outlook due to softer pet healthcare demand. Cash flow improved in 2025 with net cash flow of $325 million, but debt-to-asset ratio remains elevated at 46.14%.

The outlook is cautious with near-term headwinds in companion animal markets, but long-term fundamentals remain solid given the company's leading position in animal health. Risks include competitive pressures and a class action lawsuit. Analyst consensus is a Buy with a $95.00 price target, implying significant upside if execution improves.

Returns comparison

Trailing returns across standard periods

About Five Below Inc

Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics

Read more on FIVE

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS